Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	330.87M
Revenue (ttm)	143.68M
Net Income (ttm)	-68.20M
Shares Out	27.12M
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296,839
Open	12.27
Previous Close	12.30
Day's Range	12.07 - 12.55
52-Week Range	8.04 - 25.88
Beta	2.27
Analysts	Strong Buy
Price Target	52.83 (+333.03%)
Earnings Date	Aug 11, 2025

About X

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOS...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 176
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Financial Performance

In 2024, ARCT's revenue was $152.31 million, a decrease of -8.69% compared to the previous year's $166.80 million. Losses were -$80.94 million, 172.3% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for ARCT stock is "Strong Buy." The 12-month stock price target is $52.83, which is an increase of 333.03% from the latest price.

Price Target

$52.83

(333.03% upside)

Analyst Consensus: Strong Buy